The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?

References

• Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.
   PubMed Web of Science ®Google Scholar
• Pillaiyar T, Meenakshisundaram S, Manickam M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov Today. 2020;25(4):668–688.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.
   PubMed Web of Science ®Google Scholar
• Beauchamp LC, Finkelstein DI, Bush AI, et al. Parkinsonism as a third wave of the COVID-19 pandemic? J Parkinsons Dis. 2020;10(4):1343–1353.
   PubMedGoogle Scholar
• Baker HA, Safavynia SA, Evered LA. The ‘third wave’: impending cognitive and functional decline in COVID-19 survivors. Br J Anaesth. 2021;26(1):44–47.
   Google Scholar
• Soriano V, de Mendoza C, Gómez-Gallego F, et al. Third wave of COVID-19 in Madrid, Spain. Int J Infect Dis. 2021;107:212–214.
   PubMed Web of Science ®Google Scholar
• Yamayoshi S, Yasuhara A, Ito M, et al. Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine. 2021;32:100734.
   PubMedGoogle Scholar
• Marot S, Malet I, Leducq V, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021;12(1):844. DOI:10.1038/s41467-021-21111-9.
   PubMed Web of Science ®Google Scholar
• Abdel Latif A, Mullen J, Alkuzweny M, et al. AY.4.2 lineage report. The Center for Viral Systems Biology. outbreak.info. 2021 [cited 2021 Nov 9]. p. 1–2. Available from: https://outbreak.info/situation-reports?pango=AY.4.2.
   Google Scholar
• Haveri A, Ekström N, Solastie A, et al. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans. Eur J Immunol. 2021;51(12):3202–3213.
   PubMed Web of Science ®Google Scholar
• Te Velthuis AJW, van den Worm She, Snijder EJ, et al. The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension. Nucleic Acids Res. 2012;40(4):1737–1747.
   PubMed Web of Science ®Google Scholar
• Cevik M, Bamford CGG, Ho A. COVID-19 pandemic—a focused review for clinicians. Clin Microbiol Infect. 2020;26(7):842–847.
   PubMed Web of Science ®Google Scholar
• Prabakaran P, Xiao X, Dimitrov DS. A model of the ACE2 structure and function as a SARS-CoV receptor. Biochem Biophys Res Commun. 2004;314(1):235–241.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV - A target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
   PubMed Web of Science ®Google Scholar
• Ramajayam R, Tan KP, Liang PH. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Biochem Soc Trans. 2011;39(5):1371–1375.
   PubMedGoogle Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
   PubMed Web of Science ®Google Scholar
• Ahlén G, Frelin L, Nikouyan N, et al. The SARS-CoV-2 N protein is a good component in a vaccine. J Virol. 2020;94(18):e01279–20.
   PubMed Web of Science ®Google Scholar
• Dutta NK, Mazumdar K, Gordy JT. The nucleocapsid protein of SARS–CoV-2: a target for vaccine development. J Virol. 2020;94(13):e00647–20.
   PubMed Web of Science ®Google Scholar
• Heide J, Schulte S, Kohsar M, et al. Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19. PLoS Pathog. 2021;17(9):e1009842.
   PubMed Web of Science ®Google Scholar
• Song P, Li W, Xie J, et al. Cytokine storm induced by SARS-CoV-2. Clin Chim Acta. 2020;509:280–287.
   PubMed Web of Science ®Google Scholar
• Salvatori G, Luberto L, Maffei M, et al. SARS-CoV-2 spike protein: an optimal immunological target for vaccines. J Transl Med. 2020;18(1):222.
   PubMed Web of Science ®Google Scholar
• Park JE, Li K, Barlan A, et al. Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci. 2016;113(43):12262–12267.
   PubMed Web of Science ®Google Scholar
• Shirogane Y, Takeda M, Iwasaki M, et al. Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2. J Virol. 2008;82(17):8942–8946.
   PubMed Web of Science ®Google Scholar
• Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87(23):12552–12561.
   PubMed Web of Science ®Google Scholar
• Bertram S, Glowacka I, Muller MA, et al. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 2011;85(24):13363–13372.
   PubMed Web of Science ®Google Scholar
• Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol. 2013;87(11):6150–6160.
   PubMed Web of Science ®Google Scholar
• Palit P, Chattopadhyay D, Thomas S, et al. Phytopharmaceuticals mediated furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19? Phytomedicine. 2021;85:153396.
   PubMed Web of Science ®Google Scholar
• Johnson BA, Xie X, Bailey AL, et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021;591(7849):293–299.
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.
   PubMed Web of Science ®Google Scholar
• Stobart CC, Sexton NR, Munjal H, et al. Chimeric exchange of coronavirus nsp5 proteases (3CLpro) identifies common and divergent regulatory determinants of protease activity. J Virol. 2013;87(23):12611–12618.
   PubMed Web of Science ®Google Scholar
• Hu T, Chen C, Li H, et al. Structural basis for dimerization and RNA binding of avian infectious bronchitis virus nsp9. Protein Sci. 2017;26(5):1037–1048.
   PubMed Web of Science ®Google Scholar
• Egloff MP, Ferron F, Campanacci V, et al. The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci USA. 2004;101(11):3792–3796.
   PubMed Web of Science ®Google Scholar
• Chan JFW, Kok KH, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236.
   PubMed Web of Science ®Google Scholar
• Angeletti S, Benvenuto D, Bianchi M, et al. COVID-2019: the role of the nsp2 and nsp3 in its pathogenesis. J Med Virol. 2020;92(6):584–588.
   PubMed Web of Science ®Google Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
   PubMed Web of Science ®Google Scholar
• Shurin M. Cancer as an immune-mediated disease. Immunotargets Ther. 2012;1:1–6.
   PubMedGoogle Scholar
• Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–584.
   PubMed Web of Science ®Google Scholar
• Guo J, Huang Z, Lin L, et al. coronavirus disease 2019 (covid-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219.
   PubMed Web of Science ®Google Scholar
• Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020;5(4):562–569.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584(7821):450–456.
   PubMed Web of Science ®Google Scholar
• Piccoli L, Park YJ, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–1042.e21.
   PubMed Web of Science ®Google Scholar
• Dai L, Gao GF. Viral targets for vaccines against COVID-19. Nat Rev Immunol. 2021;21(2):73–82.
   PubMed Web of Science ®Google Scholar
• Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches. Crit Care. 2021;25(1):244.
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424.
   PubMed Web of Science ®Google Scholar
• Bian L, Gao F, Zhang J, et al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev Vaccines. 2021;20(4):365–373.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463–476.e6.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9:e61312.
   PubMed Web of Science ®Google Scholar
• Liu Z, VanBlargan LA, Bloyet LM, et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021;29(3):477–488.e4.
   PubMed Web of Science ®Google Scholar
• Thomson EC, Rosen LE, Shepherd JG, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184(5):1171–1187.e20.
   PubMed Web of Science ®Google Scholar
• Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295–1310.e20.
   PubMed Web of Science ®Google Scholar
• Sanches PRS, Charlie-Silva I, Braz HLB, et al. Recent advances in SARS-CoV-2 spike protein and RBD mutations comparison between new variants Alpha (B.1.1.7, United Kingdom), Beta (B.1.351, South Africa), Gamma (P.1, Brazil) and Delta (B.1.617.2, India). J Virus Erad. 2021;7(3):100054.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Plante KS, et al. The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv. 2021
   Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2. Science. 2020;369(6504):650–655.
   PubMed Web of Science ®Google Scholar
• McCarthy KR, Rennick LJ, Nambulli S, et al. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371(6534):1139–1142.
   PubMed Web of Science ®Google Scholar
• Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020
   Google Scholar
• Gobeil SMC, Janowska K, McDowell S, et al. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science. 2021;373(6555).
   PubMed Web of Science ®Google Scholar
• Cascella M, Rajnik M, Aleem A, et al. Features, evaluation, and treatment of coronavirus (COVID-19) In: statPearls. Treasure Island (FL): StatPearls Publishing; Internet, Jan 2022
   Google Scholar
• Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States-challenges and opportunities. JAMA. 2021;325(11):1037–1038.
   PubMed Web of Science ®Google Scholar
• Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372(6538).
   Web of Science ®Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv.2021
   Google Scholar
• Murayama H, Kayano T, Nishiura H. Estimating COVID-19 cases infected with the variant alpha (VOC 202012/01): an analysis of screening data in Tokyo, January-March 2021. Theor Biol Med Model. 2021;18(1):13.
   PubMed Web of Science ®Google Scholar
• Takano K, Watanabe Y, Hariu M, et al. Detection of representative mutant strains and a case of prolonged infection by SARS-CoV-2 with spike 69/70 deletion in Japan. Infect Drug Resist. 2021;14:2579–2581.
   PubMed Web of Science ®Google Scholar
• Lubinski B, Fernandes MHV, Frazier L, et al. Functional evaluation of the P681H mutation on the proteolytic activation the SARS-CoV-2 variant B.1.1.7 (Alpha) spike. bioRxiv. 2021.
   PubMedGoogle Scholar
• Vasireddy D, Vanaparthy R, Mohan G, et al. Review of COVID-19 variants and COVID-19 vaccine efficacy: what the clinician should know. J Clin Med Res. 2021;13(6):317–325.
   PubMedGoogle Scholar
• Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv. 2021.
   Google Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv. 2021.
   Google Scholar
• Mwenda M, Saasa N, Sinyange N, et al. Detection of B.1.351 SARS-CoV-2 variant strain-Zambia, December 2020. MMWR Morb Mortal Wkly Rep. 2021;70(8):280–282.
   PubMed Web of Science ®Google Scholar
• Faria NR, Mellan TA, Whittaker C, et al. Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus. Brazil. medRxiv. 2021;
   Google Scholar
• Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. New Engl J Med. 2021;385(7):585–594.
   PubMed Web of Science ®Google Scholar
• Aleem A, Samad ABA, Slenker AK. Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan.
   Google Scholar
• Bolze A, Cirulli ET, Luo S, et al. SARS-CoV-2 variant Delta rapidly displaced variant Alpha in the United States and led to higher viral loads. medRxiv.
   Google Scholar
• Update on Omicron. [cited 2022 Mar 22]. Available from: https://www.who.int/news/item/28-11-2021-update-on-omicron.
   Google Scholar
• GISAID - hCov19 variants. [cited 2022 Mar 22]. Available from: https://www.gisaid.org/hcov19-variants/.
   Google Scholar
• Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44–57.e9.
   PubMed Web of Science ®Google Scholar
• Zhong J, Tang J, Ye C, et al. The immunology of COVID-19: is immune modulation an option for treatment? Lancet Rheumatol. 2020;2(7):e428–e436.
   PubMedGoogle Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Fathi N, Rezaei N. Lymphopenia in COVID-19: therapeutic opportunities. Cell Biol Int. 2020;44(9):1792–1797.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Fang Y, Zhang H, Xu Y, et al. CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):208–209.
   PubMed Web of Science ®Google Scholar
• Meckiff BJ, Ramírez-Suástegui C, Fajardo V, et al. Single-cell transcriptomic analysis of SARS-CoV-2 reactive CD4+ T cells. SSRN. 2020;3641939. DOI:10.2139/ssrn.3641939
   Google Scholar
• Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.e15.
   PubMed Web of Science ®Google Scholar
• Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587(7833):270–274.
   PubMed Web of Science ®Google Scholar
• Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020;370(6512):89–94.
   PubMed Web of Science ®Google Scholar
• Jeong H, Choi YM, Seo H, et al. A novel DNA vaccine against SARS-CoV-2 encoding a chimeric protein of its receptor-binding domain (RBD) fused to the amino-terminal region of hepatitis B virus preS1 with a W4P mutation. Front Immunol. 2021;12:637654.
   PubMed Web of Science ®Google Scholar
• Brisse M, Vrba SM, Kirk N, et al. Emerging concepts and technologies in vaccine development. Front Immunol. 2020;11:583077.
   PubMed Web of Science ®Google Scholar
• Du L, Zhao G, Chan CCS, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009;393(1):144–150.
   PubMed Web of Science ®Google Scholar
• Liu H, Su D, Zhang J, et al. Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo. Sci Rep. 2017;7(1):8953.
   PubMedGoogle Scholar
• Dai L, Zheng T, Xu K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell. 2020;182(3):722–733.e11.
   PubMed Web of Science ®Google Scholar
• Shahid F, Zaheer T, Ashraf ST, et al. Chimeric vaccine designs against Acinetobacter baumannii using pan genome and reverse vaccinology approaches. Sci Rep. 2021;11(1):13213.
   PubMed Web of Science ®Google Scholar
• Rahman MS, Hoque MN, Islam MR, et al. Epitope-based chimeric peptide vaccine design against S, M and e proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach. PeerJ. 2020;8:e9572.
   PubMed Web of Science ®Google Scholar
• Fan X, Cao D, Kong L, et al. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. Nat Commun. 2020;11(1):3618.
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Jiang S, Du L. Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018;17(8):677–686.
   PubMed Web of Science ®Google Scholar
• Zakhartchouk AN, Sharon C, Satkunarajah M, et al. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine. 2007;25(1):136–143.
   PubMed Web of Science ®Google Scholar
• Woo PCY, Lau SKP, Tsoi HW, et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005;23(42):4959–4968.
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Y, Liu S, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun. 2004;324(2):773–781.
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasllieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–454.
   PubMed Web of Science ®Google Scholar
• Tai W, Zhang X, Drelich A, et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020;30(10):932–935.
   PubMed Web of Science ®Google Scholar
• Lu J, Lu G, Tan S, et al. A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice. Cell Res. 2020;30(10):936–939.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–577.
   PubMed Web of Science ®Google Scholar
• Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. 2020;11:298.
   PubMed Web of Science ®Google Scholar
• Li E, Chi H, Huang P, et al. A novel bacterium-like particle vaccine displaying the MERS-CoV receptor-binding domain induces specific mucosal and systemic immune responses in mice. Viruses. 2019;11(9):799.
   PubMed Web of Science ®Google Scholar
• Nyon MP, Du L, Tseng CTK, et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018;36(14):1853–1862.
   PubMed Web of Science ®Google Scholar
• Wang C, Zheng X, Gai W, et al. Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice. Antiviral Res. 2017;140:55–61.
   PubMed Web of Science ®Google Scholar
• Zhu X, Liu Q, Du L, et al. Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013;2(Suppl 2):S142–148. 5 Suppl.
   Google Scholar
• Lan J, Yao Y, Deng Y, et al. Recombinant receptor binding domain protein induces partial protective immunity in Rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2(10):1438–1446.
   PubMed Web of Science ®Google Scholar
• McBride R, van Zyl M, Fielding BC. The coronavirus nucleocapsid is a multifunctional protein. Viruses. 2014;6(8):2991–3018.
   PubMed Web of Science ®Google Scholar
• Gao T, Hu M, Zhang X, et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv.2020
   Google Scholar
• He R, Dobie F, Ballantine M, et al. Analysis of multimerization of the SARS coronavirus nucleocapsid protein. Biochem Biophys Res Commun. 2004;316(2):476–483.
   PubMed Web of Science ®Google Scholar
• Narayanan K, Kim KH, Makino S. Characterization of N protein self-association in coronavirus ribonucleoprotein complexes. Virus Res. 2003;98(2):131–140.
   PubMed Web of Science ®Google Scholar
• Narayanan K, Maeda A, Maeda J, et al. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol. 2000;74(17):8127–8134.
   PubMed Web of Science ®Google Scholar
• Schelle B, Karl N, Ludewig B, et al. Nucleocapsid protein expression facilitates coronavirus replication. Advances in experimental medicine and biology. Adv Exp Med Biol. 2006;581:43–48.
   PubMed Web of Science ®Google Scholar
• Batra M, Tian R, Zhang C, et al. Role of IgG against N-protein of SARS-CoV2 in COVID19 clinical outcomes. Sci Rep. 2021;11(1):3455.
   PubMedGoogle Scholar
• Hou H, Wang T, Zhang B, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunol. 2020;9(5):e1136.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang J, Xu X, et al. Patterns of IgG and IgM antibody response in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):1269–1274.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821):353–363
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Flipse J, Diosa-Toro MA, Hoornweg TE, et al. Antibody-dependent enhancement of dengue virus infection in primary human macrophages; balancing higher fusion against antiviral responses. Sci Rep. 2016;6:29201.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363–374.
   PubMed Web of Science ®Google Scholar
• Azizi A, Aucoin S, Tadesse H, et al. A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses. Genet Vaccines Ther. 2005;3(7):1–10.
   PubMedGoogle Scholar
• Seo SH, Pei J, Briles WE, et al. Adoptive transfer of infectious bronchitis virus primed alphabeta T cells bearing CD8 antigen protects chicks from acute infection. Virology. 2000;269(1):183–189.
   PubMed Web of Science ®Google Scholar
• Collisson EW, Pei J, Dzielawa J, et al. Cytotoxic T lymphocytes are critical in the control of infectious bronchitis virus in poultry. Dev Comp Immunol. 2000;24(2–3):187–200.
   PubMed Web of Science ®Google Scholar
• Buchholz UJ, Bukreyev A, Yang L, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA. 2004;101(26):9804–9809.
   PubMed Web of Science ®Google Scholar
• Yi Y, Lagniton PNP, Ye S, et al. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020;16(10):1753–1766.
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019;4(4):e123158.
   PubMed Web of Science ®Google Scholar
• Ong E, Wong MU, Huffman A, et al. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol. 2020;11:1581.
   PubMed Web of Science ®Google Scholar
• Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines: potentials and constraints. Dev Biol. 2005;121:153–163.
   Google Scholar
• Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med. 2001;193(2):169–180.
   PubMed Web of Science ®Google Scholar
• Eckels DD, Wang H, Bian TH, et al. Immunobiology of hepatitis C virus (HCV) infection: the role of CD4 T cells in HCV infection. Immunol Rev. 2000;174:90–97.
   PubMed Web of Science ®Google Scholar
• Li Z, Guo X, Hao W, et al. The relationship between serum interleukins and T-lymphocyte subsets in patients with severe acute respiratory syndrome. Chin Med J (Engl). 2003;116(7):981–984.
   PubMed Web of Science ®Google Scholar
• Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541–543.
   PubMed Web of Science ®Google Scholar
• Roper RL, Rehm KE. SARS vaccines: where are we? Exp Rev Vaccines. 2009;8(7):887–898.
   PubMed Web of Science ®Google Scholar
• de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nature Rev Microbiol. 2016;14(8):523–534.
   PubMed Web of Science ®Google Scholar
• Thieme CJ, Anft M, Paniskaki K, et al. Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep Med. 2020;1(6):100092.
   PubMedGoogle Scholar
• Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–644.
   PubMed Web of Science ®Google Scholar
• Kim TW, Lee JH, Hung C-F, et al. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol. 2004;78(9):4638–4645.
   PubMed Web of Science ®Google Scholar
• Wesseling JG, Godeke GJ, Schijns VECJ, et al. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J Gen Virol. 1993;74(Pt 10):2061–2069.
   PubMedGoogle Scholar
• Wasmoen TL, Kadakia NP, Unfer RC, et al. Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus. Adv Exp Med Biol. 1995;380:221–228.
   PubMedGoogle Scholar
• Saleh M, Nowroozi J, Farahmand B, et al. An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge. Biotech Lett. 2020;42(7):1147–1159. DOI:10.1007/s10529-020-02822-3
   PubMed Web of Science ®Google Scholar
• Gao W, Tamin A, Soloff A, et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet. 2003;362(9399):1895–1896.
   PubMed Web of Science ®Google Scholar
• Roose K, Fiers W, Saelens X. Pandemic preparedness: toward a universal influenza vaccine. Drug News Perspect. 2009;22(2):80–92.
   PubMedGoogle Scholar
• van de Sandt Ce, Dou YY, Vogelzang-van Trierum SE, et al. Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. J Gen Virol. 2015;96(8):2061–2073.
   PubMedGoogle Scholar
• Kreijtz JHCM, Bodewes R, van Amerongen G, et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine. 2007;25(4):612–620.
   PubMed Web of Science ®Google Scholar
• See RH, Zakhartchouk AN, Petric M, et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol. 2006;87(Pt 3):641–650.
   PubMedGoogle Scholar
• Pang H, Liu Y, Han X, et al. Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine. J Gen Virol. 2004;85(Pt 10).
   PubMedGoogle Scholar
• Zhu MS, Pan Y, Chen HQ, et al. Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine. Immunol Lett. 2004;92(3):237–243.
   PubMed Web of Science ®Google Scholar
• Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003;13(6):387–398.
   PubMed Web of Science ®Google Scholar
• Bournazos S, Gupta A, v RJ. The role of IgG Fc receptors in antibody-dependent enhancement. Nat Rev Immunol. 2020;20(10):633–643.
   PubMed Web of Science ®Google Scholar
• DRAFT landscape of COVID-19 candidate vaccines-26 November 2020;1–12. Available from: https://www.who.int/docs/default-source/blue-print/novel-coronavirus-landscape-covid-19-(7).pdf?sfvrsn=a4e55ae3_2.
   Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity. 2020;52(4):583–589.
   PubMed Web of Science ®Google Scholar
• COVID-19 vaccine tracker | RAPS. [cited Apr 14, 2020]. Available from: https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker.
   Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Engl J Med. 2021;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. New Engl J Med. 2021;384(23):2187–2201.
   PubMed Web of Science ®Google Scholar
• van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat Mater. 2020;19(8):810–812.
   PubMed Web of Science ®Google Scholar
• Kumar A, Meldgaard TS, Bertholet S. Novel platforms for the development of a universal influenza vaccine. Front Immunol. 2018;9.
   Web of Science ®Google Scholar
• Zhang J, Zeng H, Gu J, et al. Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel). 2020;8(2):1–12.
   Web of Science ®Google Scholar
• Logunov DY, Dolzhikova Z IV, OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897.
   PubMed Web of Science ®Google Scholar
• Sjcfm M, Arts RJW, van Crevel R, et al. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25(12):1473–1478.
   PubMed Web of Science ®Google Scholar
• Berg MK, Yu Q, Salvador CE, et al. Mandated Bacillus Calmette-Guérin (BCG) vaccination predicts flattened curves for the spread of COVID-19. Science Adv. 2020;6(32):eabc1463.
   PubMed Web of Science ®Google Scholar
• Curtis N, Sparrow A, Ghebreyesus TA, et al. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–1546.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, St. Denis K, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184(9):2372–2383.e9.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. New Engl J Med. 2021;384(20):1885–1898.
   PubMed Web of Science ®Google Scholar
• Trout S Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial 2021.
   Google Scholar
• Basiri A, Pazhouhnia Z, Beheshtizadeh N, et al. Regenerative medicine in COVID-19 treatment: real opportunities and range of promises. Stem Cell Rev Rep. 2021;17(1):163–175.
   PubMed Web of Science ®Google Scholar
• Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52):eabe0367.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang L, Kuwahara K, et al. Correction: immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2020;6(5):1284–1285.
   PubMed Web of Science ®Google Scholar
• Yip MS, Leung NHL, Cheung CY, et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virology J. 2014; 11: 82.
   PubMed Web of Science ®Google Scholar
• Jaume M, Yip MS, Cheung CY, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J Virol. 2011;85(20):10582–10597.
   PubMed Web of Science ®Google Scholar
• Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917–927.
   PubMed Web of Science ®Google Scholar
• Jaume M, Yip MS, Kam YW, et al. SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med J. 2012;18 Suppl 2(Suppl 2):31–36.
   PubMedGoogle Scholar
• Haagmans BL, van den Brand JMA, Raj VS, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77–81.
   PubMed Web of Science ®Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science. 2020;368(6494):945–946.
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1):1620.
   PubMed Web of Science ®Google Scholar
• Wong SK, Li W, Moore MJ, et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem. 2004;279(5):3197–3201.
   PubMed Web of Science ®Google Scholar
• Jiang H, Li Y, Zhang H, et al. Global profiling of SARS-CoV-2 specific IgG/ IgM responses of convalescents using a proteome microarray. medRxiv. 2020.
   Google Scholar
• Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26(7):1478–1488.
   PubMed Web of Science ®Google Scholar
• Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3.
   PubMed Web of Science ®Google Scholar
• Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta. 2020;507:164–166.
   PubMed Web of Science ®Google Scholar
• Shi J, Zhang J, Li S, et al. Epitope-based vaccine target screening against highly pathogenic MERS-CoV: an in silico approach applied to emerging infectious diseases. PLoS One. 2015;10(12):e0144475.
   PubMed Web of Science ®Google Scholar
• Zheng N, Xia R, Yang C, et al. Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. Vaccine. 2009;27(36):5001–5007.
   PubMed Web of Science ®Google Scholar
• Callaway E. Fast-spreading COVID variant can elude immune responses. Nature. 2021;589(7843):500–501.
   PubMed Web of Science ®Google Scholar
• Callaway E. Could new COVID variants undermine vaccines? Labs scramble to find out. Nature. 2021;589(7841):177–178.
   PubMed Web of Science ®Google Scholar
• Callaway E, Ledford H. How to redesign COVID vaccines so they protect against variants. Nature. 2021;590(7844):15–16.
   PubMed Web of Science ®Google Scholar
• Chiu NC, Chi H, Tu YK, et al. To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. Expert Rev Vaccines. 2021;20(10):1211–1220.
   PubMed Web of Science ®Google Scholar